Crown Labs and Revance Therapeutics closer to merging

Crown Laboratories and Revance Therapeutics have just announced updates to their merger agreement which is a major step toward combining the two organizations. Under the amended agreement, Crown, which makes Blue Lizard sunscreen, will acquire all outstanding shares of Revance’s stock. Revance, known for its innovative aesthetic and therapeutic offerings, will join Crown’s portfolio to create a comprehensive lineup of high-growth products in skincare and aesthetics. Revance’s board has unanimously approved the agreement, which is expected to close in early 2025. Once complete, Revance will become a wholly owned subsidiary of Crown.